NetworkNewsBreaks – Lexaria Bioscience Corp. (NA
Post# of 420
(Total Views: 52)
Posted On: 09/05/2024 4:57:34 PM
NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Appoints Medical Device and Pharmaceutical Industries Veteran as New CEO
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced the appointment of Richard Christopher as the new CEO, effective August 31, 2024. Mr. Christopher is a recognized industry veteran with over three decades of experience in the medical device and pharmaceutical industries. He has domestic and international experience in leadership, operations, acquisitions/licensing, business development, strategic planning and capital markets. Mr. Christopher takes over from outgoing CEO, Chris Bunka, who has stepped aside from the role. Mr. Bunka remains as the Chairman of the Board of Directors and has been appointed Executive Strategic Advisor to the management team.
“I’m delighted that I have been appointed to lead Lexaria,” said Mr. Christopher. “The company is well positioned for an exciting period of growth centered around the advancement and improvement of drug delivery in the GLP-1 marketplace. We are preparing for an active and collaborative new era for Lexaria in the pharmaceutical industry.”
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced the appointment of Richard Christopher as the new CEO, effective August 31, 2024. Mr. Christopher is a recognized industry veteran with over three decades of experience in the medical device and pharmaceutical industries. He has domestic and international experience in leadership, operations, acquisitions/licensing, business development, strategic planning and capital markets. Mr. Christopher takes over from outgoing CEO, Chris Bunka, who has stepped aside from the role. Mr. Bunka remains as the Chairman of the Board of Directors and has been appointed Executive Strategic Advisor to the management team.
“I’m delighted that I have been appointed to lead Lexaria,” said Mr. Christopher. “The company is well positioned for an exciting period of growth centered around the advancement and improvement of drug delivery in the GLP-1 marketplace. We are preparing for an active and collaborative new era for Lexaria in the pharmaceutical industry.”
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LEXX) Stock Research Links
Scroll down for more posts ▼